Releases
Medable Achieves Landmark CNIL Approval, Expanding Access for Digital Clinical Trials Across the European Union
Medable announced that its eConsent and eCOA solutions have been approved for use in two clinical studies in eight countries outside of the European Union by France’s Commission Nationale de l’Informatique et des Libertés (CNIL).
Medable Wins 2023 Prix Galien Award for Best Digital Health Solution
Medable was awarded ‘Best Digital Health Solution’ from a field of 24 nominees at the Prix Galien USA Forum in New York City. This recognition underscores the impact of Medable’s evidence generation platform on clinical research worldwide.
Medable Partners with Pluto Health to Optimize Patient Experience and Improve Access to Clinical Trials
This strategic partnership combines best-in-class patient care coordination service and clinical trialsplatform to streamline execution, improve data quality, and enhance patient experience.
Medable Ranks in Top 8% of 2023 Inc. 5000 List of America’s Fastest-Growing Private Companies
Medable, the leading technology provider for patient-centric clinical trials, today announced that it ranked in the top 8 percent (#398) and was one of the top 50 software companies on the 2023 Inc. 5000, its annual list of the fastest-growing private companies in America. Medable’s ranking was fueled by its strong three-year growth rate of 1,453% from 2019 through 2022.
MRCT Center and Medable Launch First, Comprehensive IRB/EC Review Toolkit for Decentralized Clinical Trials
MRCT Center and Medable launch first-of-its-kind toolkit to provide a common framework, tools, and best practices for uniform ethical review and approval to simplify, streamline, and speed the IRB/EC process – a key step towards more efficient, patient-centered research execution.
Medable Vice President of Data Analytics Steve Jones Wins Esteemed Decentralized Solutions Individual of the Year
Steve Jones, Medable’s vice president of data analytics, achieved the silver award in the Decentralized Solutions Individual of the Year category at PharmaTimes International Clinical Researcher of the Year awards gala in London on May 18, 2023.
Nova Scotia Health Partners with Medable Decentralized Trial Technology to Improve Oncology Patient Access
Medable's decentralized clinical trial (DCT) platform was selected by the Nova Scotia Health Innovation Hub to increase the accessibility of oncology care for remote patients in rural Nova Scotia, with the long-term aim to improve patient access and trial diversity across Canada.
Medable Partners with Every Cure to Accelerate Discovery of Treatments for Rare Diseases
Medable, the industry-leading technology platform for patient-centered clinical trials, today announced a partnership with non-profit Every Cure, which officially launched in September in partnership with the Clinton Global Initiative to scale up an innovative “drug repurposing” research approach to identify treatments for rare diseases.
Reuters Recognizes Medable for Innovation, Industry Impact at Pharma Awards USA 2022
Medable won the Most Valuable Clinical Technology Award and the Health Entrepreneur Award at the Reuters Pharma Awards USA 2022. This double recognition underscores Medable’s leadership in applying digital methodology to clinical research at scale.
Medable Named a Leader in Decentralized Clinical Trial Products Assessment for Second Consecutive Year by Everest Group
Medable was named a Leader in the “Decentralized Clinical Trial Products PEAK Matrix® Assessment 2022” by Everest Group for the second consecutive year. The report evaluates decentralized clinical trial (DCT) products from 24 companies. Medable rated highest in the Leaders quadrant with top scores for vision, capability and market impact.
Medable Unifies and Simplifies Consent Management for Global Decentralized and Hybrid Trials
Medable, the industry-leading technology platform for patient-centered clinical trials, today announced the availability of its Total Consent offering, a fully enabled SaaS electronic consent management solution compatible with every clinical trial, in more than 120 locales around the globe. With this launch, Medable’s Total Consent offering is at the forefront of optimizing the informed consent process for potential trial participants by improving patient accessibility, knowledge, and experience, in line with the release of the proposed FDA rule, Protection of Human Subjects and Institutional Review Boards.
Medable Enhances Patient Experience in Oncology Clinical Trials to Increase Access, Enrollment, Retention
Medable Inc., the industry-leading technology platform for patient-centered clinical trials, today announced a new patient-first oncology offering that enables life sciences companies to improve patient access, enrollment, and retention in cancer trials. Medable’s new offering is an end-to-end suite that includes pre-built and validated DCT applications such as Total Consent and Televisit, an extensive eCOA oncology library, and protocol design consulting – with a single point of entry for patients, sites and sponsors.
Medable Selected by GSK to Power Decentralized and Hybrid Clinical Trials Across Global Product Portfolio
Medable, the leading software provider for patient-centered clinical trials, today announced that it has entered a four-year enterprise contract with GSK to enable decentralized clinical trials (DCTs) across their portfolio using the company’s industry-leading DCT platform. Medable was selected by GSK to accelerate the delivery of new medicines and enable their clinical trials to be more inclusive and representative of all patient populations.